Time to get serious about HIV antiretroviral resistance

The Lancet Infectious Diseases

Volumn 11, Issue 10, 2011, Pages 723-724

  Wood, Evan ^a,b   Montaner, Julio S G ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ANTIVIRAL RESISTANCE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MORBIDITY; NIGERIA; NOTE; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; UGANDA; VIRUS LOAD; VIRUS TRANSMISSION; ZAMBIA; ZIMBABWE;

EID: 80053238942     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70216-X     Document Type: Letter

References (14)

1. Dieffenbach CW, Fauci AS Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 2011, 154:766-771.
2. Volberding PA, Deeks SG Antiretroviral therapy and management of HIV infection. Lancet 2010, 376:49-62.
3. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010, 363:1499-1509.
4. Cohen OJ, Fauci AS Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable. Lancet 1999, 354:697-698.
5. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011, 11:363-371.
6. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305:1327-1335.
7. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011, 11:750-759.
8. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010, 50:98-105.
9. Marseille E, Hofmann PB, Kahn JG HIV prevention before HAART in sub-Saharan Africa. Lancet 2002, 359:1851-1856.
10. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
11. Hirnschall G, Schwartlander B Treatment 2.0: catalysing the next phase of scale-up. Lancet 2011, 378:209-211.
12. Coates TJ, Richter L, Caceres C Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008, 372:669-684.
13. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011, 378:282-284.
14. Bangsberg DR Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008, 197(suppl 3):S272-S278.